KRAS and melanoma: For instance, Patnaik’s phase I trial in diverse solid tumors highlighted the potential of CDK4/6 inhibition as a rational strategy, particularly in KRAS-mutated non-small cell lung cancer (NSCLC) (disease control rate 55% vs. 39% in KRAS Mut vs. WT patients), as well as in melanoma patients harboring NRAS mutations.694 A subsequent JUNIPER phase III trial compared abemaciclib with erlotinib in previously treated, KRAS-mutated NSCLC patients.